Pamela Schuler

Pamela Schuler, M.D.

Clinical Associate Professor

Department: MD-PEDS-PULMONARY
Business Phone: (352) 273-8512
Business Email: schulpm@ufl.edu

Publications

2013
Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Pediatric pulmonology. 48(9):874-84 [DOI] 10.1002/ppul.22711. [PMID] 23139089.
2012
Consensus Statement On Standard of Care for Congenital Myopathies
Journal of Child Neurology. 27(3):363-382 [DOI] 10.1177/0883073812436605. [PMID] 22431881.
2012
Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children With Cystic Fibrosis
Pharmacoepidemiology and Drug Safety. 21
2012
Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab).
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 17(1):88-92 [DOI] 10.5863/1551-6776-17.1.88. [PMID] 23118662.
2012
Parental Report of Children’s Views of the Shortened Life Expectancy Associated With Cystic Fibrosis
Pediatric Pulmonology. 47:434-435
2010
Consensus statement on standard of care for congenital muscular dystrophies.
Journal of child neurology. 25(12):1559-81 [DOI] 10.1177/0883073810381924. [PMID] 21078917.
2010
Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Pediatric transplantation. 14(7):896-902 [DOI] 10.1111/j.1399-3046.2010.01370.x. [PMID] 20642490.
2009
Post-Transplant Lymphoproliferative Disorder in Children: Recent Clinical Characteristics, Outcomes and Response To Dual Rituximab/Chemotherapy Combination
American Journal of Transplantation. 9
2009
Post-Transplant Lymphoproliferative Disorder in Children: Recent Clinical Characteristics, Outcomes and Response To Dual Rituximab/Chemotherapy Combination
American Journal of Transplantation. 9

Grants

Jan 2015 – Mar 2020
Therapeutics Development Center Award
Role: Project Manager
Funding: CYSTIC FIBROSIS FOU THERAPEUTICS
Aug 2013 – Dec 2016
Telemedicine Genetic Counseling in the provision of CF Newborn Screening
Role: Project Manager
Funding: CYSTIC FIBROSIS FOU
Jan 2011 – Sep 2015
Early MRSA therapy in CF culture based vs. observant therapy (treat or observe) (STAR-too STtaph Aureus Resistance treat or observe)
Role: Principal Investigator
Funding: UNIV OF NORTH CAROLINA via CYSTIC FIBROSIS FOU THERAPEUTICS

Contact Details

Phones:
Business:
(352) 273-8512
Emails:
Business:
schulpm@ufl.edu